You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. General Purpose Radiation Detector Front End and Digital Processor

    SBC: H3D, Inc.            Topic: DTRA20B002

    This project aims to create a general-purpose readout architecture that will allow the rapid deployment of next generation detection systems. The system will be based on the development of a programmable general-purpose integrated circuit (GPIC) that has the front-end electronics required to read out signals from a variety of radiation detectors, especially next generation scintillators and semico ...

    STTR Phase I 2021 Department of DefenseDefense Threat Reduction Agency
  2. Development of Innovative Medical Device Technology for Quantifying Forces during Soft Tissue Manipulation Assessment and Intervention

    SBC: Health Smart Technologies, Inc            Topic: R

    PROJECT SUMMARY The lack of a means to quantify soft tissue manipulation (STM) motion and dose as delivered in the clinic is a critical problem in the reproducibility and therapeutic potential of this non-invasive and non-pharmacological modality. STM is a form of manual therapy used to evaluate and treat musculoskeletal pain, inflammation, and dysfunction. Different soft tissue forces have differ ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  3. New Treatments for Glaucoma

    SBC: Grannus Therapeutics, Inc.            Topic: NEI

    Abstract Aggregation of mutated myocilin (MYOC), a protein found in the endoplasmic reticulum (ER) of trabecular meshwork (TM) cells, disrupts the outflow of aqueous humor from the eye, causing increase in intraocular pressure (IOP), progressive retinal ganglion cell (RGC) death, and degeneration of the optic nerve, leading to primary open-angle glaucoma (POAG), characterized by irreversible visio ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  4. High-density optical tomography of cerebral blood flow and metabolism in small animals

    SBC: Bioptics Technology LLC            Topic: 105

    ABSTRACT Many clinical situations, including stroke, expose the brain to insufficient cerebral blood flow (CBF) that cannot maintain normal cerebral metabolic rate of oxygen consumption (CMRO2) requirements, thereby leading to cerebral ischemic/hypoxic stresses and neurological disorders. Effective interventions are dependent on the findings of CBF/CMRO2 improvement and eventually neural recovery. ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  5. Modular Adaptive Virtual Reality Intervention for Clinical Substance use disorder (MAVRICS)

    SBC: INNATEVR LLC            Topic: NIDA

    PROJECT SUMMARY/ABSTRACT Opioid Use Disorder (OUD) is a chronic, recurring condition that if left untreated, poses a significant and ongoing public health threat. OUD is associated with significant impairments in physical and psychological health including increased mortality and high utilization of emergency medical care as well as increased risk of Hepatitis C and HIV infection and Neonatal Abst ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  6. Avoiding Adverse Opioid Outcomes with Proactive Precision Care

    SBC: OpalGenix, Inc.            Topic: NIDA

    PROJECT SUMMARY FOR PREDICATE STTR PHASE I GRANT Perioperative and prescribed opioids often result in costly and unpredictable adverse effects, including life threatening respiratory depression and long-term opioid use/misuse in vulnerable patients. The US FDA warns against the use of codeine and tramadol in children due to postoperative anoxic brain injuries and deaths, and in nursing mothers due ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  7. Development of Novel Therapeutic Molecules for Treatment of Squamous Head and Neck Cancers

    SBC: Mekanistic Therapeutics, LLC            Topic: 102

    Mekanistic Therapeutics seeks to design, discover, and develop anti-cancer agents that selectively inhibit multiple oncogenic pathways. Among Mekanistic’s portfolio are dual and highly selective inhibitors of EGFR and PI3 kinase, which were rationally designed to only target these two critical oncogenes. The PI3 kinase (PI3K)/AKT/mTOR pathway plays a central role in driving tumor cell survival a ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  8. Novel QcrB Inhibitors for the Treatment of Tuberculosis

    SBC: LGENIA INC.            Topic: NIAID

    Abstract Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is the biggest killer among infectious diseases. TB is also responsible for a quarter of all deaths associated with Antimicrobial Resistance (AMR). It is projected that by 2050, 75 million people, or one person every 12 seconds, will die due to AMR associated with TB. Long treatment times and increasing resistance to TB drugs ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. Cerenkov Multi-Spectral Imaging (CMSI) for Adaptation and Real-Time Imaging in Radiotherapy

    SBC: ENDECTRA, LLC            Topic: 102

    PROJECT SUMMARY Understanding of tumor molecular characteristics during a course of radiotherapy (RT) treatment is crucial to assess the efficacy of the treatment and adapt radiation dosage to optimize outcomes. Unfortunately, this cannot be routinely achieved by current diagnostic nuclear imaging modalities due to complex logistics and prohibitive costs. Alternatively, Cerenkov Emission (CE) is a ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Novel Nanosecond Laser and Ultrasound to Selectively Treat Eye Blood Vessels

    SBC: Photosonox LLC            Topic: NEI

    ABSTRACT / PROJECT SUMMARY Wet age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the developed world. Anti-VEGF therapy is currently the gold standard for wet AMD treatment. However, up to 50% of patients in the long term have a suboptimal response to anti-VEGF therapy. A better alternative method for treatment of AMD is urgently needed. We have recently inve ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government